Global Alpha- Antitrypsin Deficiency Treatment Market - Industry Dynamics, Market Size, And Opportunity Forecast To 2028
Global Alpha- Antitrypsin Deficiency Treatment Market - Industry Dynamics, Market Size, And Opportunity Forecast To 2028
Get latest Market Research Reports on Alpha- Antitrypsin Deficiency Treatment. Industry analysis and Market Report on Alpha- Antitrypsin Deficiency Treatment is a syndicated market report, published as Global Alpha- Antitrypsin Deficiency Treatment Market Research Report . It is complete Research Study and Industry Analysis of Alpha- Antitrypsin Deficiency Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period.
Data collected includes market dynamics, technology outlook, application development, and pricing trends. All of this is fed into a research model, which then produces relevant data for market research. Global market trend analysis is given including historical data, estimates to 2023 and compound annual growth rate (CAGR) forecast to 2028.
Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation.
2023 will be a tough year for much of the global economy, as the ongoing war in Ukraine continues to strain trade, especially in Europe, and the global economy remains reeling from the fallout from the COVID-19 pandemic.
But as China moves ever closer to fully reemerging from three years of government-imposed Covid isolation and reintegrating with the world, economic expectations are high.And with the global economy now facing significant challenges, including energy shortages, slowing growth and high inflation, China’s reopening could provide a much-needed and timely boost.
The report researches and analyzes the influence of the Alpha- Antitrypsin Deficiency Treatment industry in the new era of global post-COIVD-19 economy in 2023, and provides in-depth analysis and professional suggestions on the current development.
Market Segment by Product Type
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Market Segment by Product Application
Clinic
Hospital
Others
Finally, the report provides detailed profile and data information analysis of leading company.
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Insights and Tools:
We follow a comprehensive process to estimate market size. Key industry dynamics, regulatory scenarios, and segmental dynamics are analyzed to understand their impact on demand over the forecast period. Macroeconomic indicators such as prices, income and demographic changes, demand changes, etc. are considered in estimating market size. We also provide an in-depth profile of the key players and discuss their market shares in the global market to derive the market value. In addition, we have an internal database that is regularly updated with key insights and press releases from key stakeholders in the relevant market.
The data is generally gathered in various arrangements such as charts, graphs, infographics, trends, documents and records from various manufacturers and retailers. Our analyst gather, collect, and interpret such data to form significant databases. Our team then works with large data volumes to analyze core developments, evaluate market estimations, and identify trends.
The market research includes historical and forecast data from like demand, application details, price trends, and company shares by geography, especially focuses on the key regions like United States, European Union, China, and other regions.
Research Objectives
1.To study and analyze the global Alpha- Antitrypsin Deficiency Treatment consumption (value) by key regions/countries, product type and application, history data from 2018 to 2022, and forecast to 2028.
2.To understand the structure of Alpha- Antitrypsin Deficiency Treatment market by identifying its various subsegments.
3.Focuses on the key global Alpha- Antitrypsin Deficiency Treatment manufacturers, to define, describe and analyze the value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.
4.To analyze the Alpha- Antitrypsin Deficiency Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
5.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
6.To project the consumption of Alpha- Antitrypsin Deficiency Treatment submarkets, with respect to key regions (along with their respective key countries).
7.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
8.To strategically profile the key players and comprehensively analyze their growth strategies.
Global Alpha- Antitrypsin Deficiency Treatment Market Research Report 2023, Forecast to 2028
1 Market Study Overview
1.1 Study Objectives
1.2 Alpha- Antitrypsin Deficiency Treatment Introduce
1.3 Combined with the Analysis of Macroeconomic Indicators
1.4 Brief Description of Research methods
1.5 Market Breakdown and Data Triangulation
2 Global Trend Summary
2.1 Alpha- Antitrypsin Deficiency Treatment Segment by Type
2.1.1 CT-2009
2.1.2 POL-6014
2.1.3 ARO-AAT
2.1.4 ALNAAT-02
2.1.5 Others
2.2 Market Analysis by Application
2.2.1 Clinic
2.2.2 Hospital
2.2.3 Others
2.3 Global Alpha- Antitrypsin Deficiency Treatment Market Comparison by Regions (2018-2028)
2.3.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size (2018-2028)
2.3.2 North America Alpha- Antitrypsin Deficiency Treatment Status and Prospect (2018-2028)
2.3.3 Europe Alpha- Antitrypsin Deficiency Treatment Status and Prospect (2018-2028)
2.3.4 China Alpha- Antitrypsin Deficiency Treatment Status and Prospect (2018-2028)
2.3.5 Japan Alpha- Antitrypsin Deficiency Treatment Status and Prospect (2018-2028)
2.3.6 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Status and Prospect (2018-2028)
2.4 Basic Product Information
2.4.1 Basic Product Information & Technology Development History
2.4.2 Product Manufacturing Process
2.4.3 Interview with Major Market Participants
2.4.4 High-end Market Analysis and Forecast
2.5 Coronavirus Disease 2020 (Covid-19): Alpha- Antitrypsin Deficiency Treatment Industry Impact
2.5.1 Alpha- Antitrypsin Deficiency Treatment Business Impact Assessment - Covid-19
2.5.2 Market Trends and Alpha- Antitrypsin Deficiency Treatment Potential Opportunities in the COVID-19 Landscape
2.5.3 Measures / Proposal against Covid-19
3 Competition by Manufacturer
3.1 Global Alpha- Antitrypsin Deficiency Treatment Sales and Market Share by Manufacturer (2018-2023)
3.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue and Market Share by Manufacturer (2018-2023)
3.3 Global Alpha- Antitrypsin Deficiency Treatment Industry Concentration Ratio (CR5 and HHI)
3.4 Top 5 Alpha- Antitrypsin Deficiency Treatment Manufacturer Market Share
3.5 Top 10 Alpha- Antitrypsin Deficiency Treatment Manufacturer Market Share
3.6 Date of Key Manufacturers Enter into Alpha- Antitrypsin Deficiency Treatment Market
3.7 Key Manufacturers Alpha- Antitrypsin Deficiency Treatment Key Manufacturers
3.8 Mergers & Acquisitions Planning
4 Analysis of Alpha- Antitrypsin Deficiency Treatment Industry Key Manufacturers
4.1 Adverum Biotechnologies, Inc.
4.1.1 Compan Detail
4.1.2 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.1.3 Adverum Biotechnologies, Inc. 166 Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.1.4 Main Business Overview
4.1.5 Adverum Biotechnologies, Inc. News
4.2 Alnylam Pharmaceuticals, Inc.
4.2.1 Compan Detail
4.2.2 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.2.4 Main Business Overview
4.2.5 Adverum Biotechnologies, Inc. News
4.3 Applied Genetic Technologies Corporation
4.3.1 Compan Detail
4.3.2 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.3.4 Main Business Overview
4.3.5 Applied Genetic Technologies Corporation News
4.4 Arrowhead Pharmaceuticals, Inc.
4.4.1 Compan Detail
4.4.2 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.4.4 Main Business Overview
4.4.5 Arrowhead Pharmaceuticals, Inc. News
4.5 Carolus Therapeutics, Inc.
4.5.1 Compan Detail
4.5.2 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.5.4 Main Business Overview
4.5.5 Carolus Therapeutics, Inc. News
4.6 Cevec Pharmaceuticals GmbH
4.6.1 Compan Detail
4.6.2 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.6.4 Main Business Overview
4.6.5 Cevec Pharmaceuticals GmbH News
4.7 Dicerna Pharmaceuticals, Inc.
4.7.1 Compan Detail
4.7.2 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.7.4 Main Business Overview
4.7.4 Main Business Overview
4.8 Digna Biotech, S.L.
4.8.1 Compan Detail
4.8.2 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.8.4 Main Business Overview
4.8.5 Digna Biotech, S.L. News
4.9 Editas Medicine, Inc.
4.9.1 Compan Detail
4.9.2 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.9.4 Main Business Overview
4.9.5 Editas Medicine, Inc. News
4.10 Grifols, S.A.
4.10.1 Compan Detail
4.10.2 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.10.4 Main Business Overview
4.10.5 Grifols, S.A. News
4.11 Inhibrx
4.11.1 Compan Detail
4.11.2 Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.11.4 Main Business Overview
4.11.5 Inhibrx News
4.12 Intellia Therapeutics, Inc.
4.12.1 Compan Detail
4.12.2 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.12.4 Main Business Overview
4.12.5 Intellia Therapeutics, Inc. News
4.13 International Stem Cell Corporation
4.13.1 Company Details
4.13.2 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.13.4 Main Business Overview
4.13.5 International Stem Cell Corporation News
4.14 Ionis Pharmaceuticals, Inc.
4.14.1 Compan Detail
4.14.2 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.14.4 Main Business Overview
4.14.5 Ionis Pharmaceuticals, Inc. News
4.15 Kamada Ltd.
4.15.1 Compan Detail
4.15.2 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.15.4 Main Business Overview
4.15.5 Kamada Ltd. News
4.16 Polyphor Ltd.
4.16.1 Compan Detail
4.16.2 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.16.4 Main Business Overview
4.16.5 Polyphor Ltd. News
4.17 ProMetic Life Sciences Inc.
4.17.1 Compan Detail
4.17.2 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.17.4 Main Business Overview
4.17.5 ProMetic Life Sciences Inc. News
4.18 rEVO Biologics, Inc.
4.18.1 Compan Detail
4.18.2 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.18.4 Main Business Overview
4.18.5 rEVO Biologics, Inc. News
4.19 Sangamo BioSciences, Inc.
4.19.1 Compan Detail
4.19.2 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product Introduction, Application and Specification
4.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Sales, Price, Cost, Gross Margin, and Revenue (2018-2023)
4.19.4 Main Business Overview
4.19.5 Sangamo BioSciences, Inc. News
5 Global Alpha- Antitrypsin Deficiency Treatment Market Segment by Big Type
5.1 Global Alpha- Antitrypsin Deficiency Treatment Revenue, Sales and Market Share by Big Type (2018-2023)
5.1.1 Global Alpha- Antitrypsin Deficiency Treatment Sales and Market Share by Big Type (2018-2023)
5.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue and Market Share by Big Type (2018-2023)
5.2 CT-2009 Sales Growth Rate and Price
5.2.1 Global CT-2009 Sales Growth Rate (2018-2023)
5.2.2 Global CT-2009 Price (2018-2023)
5.3 POL-6014 Sales Growth Rate and Price
5.3.1 Global POL-6014 Sales Growth Rate (2018-2023)
5.3.2 Global POL-6014 Price (2018-2023)
5.4 ARO-AAT Sales Growth Rate and Price
5.4.1 Global ARO-AAT Sales Growth Rate (2018-2023)
5.4.2 Global ARO-AAT Price (2018-2023)
5.5 ALNAAT-02 Sales Growth Rate and Price
5.5.1 Global ALNAAT-02 Sales Growth Rate (2018-2023)
5.5.2 Global ALNAAT-02 Price (2018-2023)
5.6 Others Sales Growth Rate and Price
5.6.1 Global Others Sales Growth Rate (2018-2023)
5.6.2 Global Others Price (2018-2023)
6 Global Alpha- Antitrypsin Deficiency Treatment Market Segment by Big Application
6.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Big Application (2018-2023)
6.2 Clinic Sales Growth Rate (2018-2023)
6.3 Hospital Sales Growth Rate (2018-2023)
6.4 Others Sales Growth Rate (2018-2023)
7 Global Alpha- Antitrypsin Deficiency Treatment Forecast
7.1 Global Alpha- Antitrypsin Deficiency Treatment Revenue, Sales and Growth Rate (2023-2028)
7.2 Alpha- Antitrypsin Deficiency Treatment Market Forecast by Regions (2023-2028)
7.2.1 North America Alpha- Antitrypsin Deficiency Treatment Market Forecast (2023-2028)
7.2.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Forecast (2023-2028)
7.2.3 China Alpha- Antitrypsin Deficiency Treatment Market Forecast (2023-2028)
7.2.4 Japan Alpha- Antitrypsin Deficiency Treatment Market Forecast (2023-2028)
7.2.5 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Forecast (2023-2028)
7.2.6 Other Regions Alpha- Antitrypsin Deficiency Treatment Market Forecast (2023-2028)
7.3 Alpha- Antitrypsin Deficiency Treatment Market Forecast by Type (2023-2028)
7.3.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Type (2023-2028)
7.3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Type (2023-2028)
7.4 Alpha- Antitrypsin Deficiency Treatment Market Forecast by Application (2023-2028)
7.4.1 Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Application (2023-2028)
7.4.2 Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Application (2023-2028)
8 Market Analysis
8.1.1 Market Overview
8.1.2 Market Opportunities
8.1.3 Market Risk
8.1.4 Market Driving Force
8.1.5 Porter's Five Forces Analysis
8.1.6 SWOT Analysis
9 Alpha- Antitrypsin Deficiency Treatment Related Market Analysis
9.1 Upstream Analysis
9.1.1 Macro Analysis of Upstream Markets
9.1.2 Key Players in Upstream Markets
9.1.3 Upstream Market Trend Analysis
9.1.4 Alpha- Antitrypsin Deficiency Treatment Manufacturing Cost Analysis
9.2 Downstream Market Analysis
9.2.1 Macro Analysis of Down Markets
9.2.2 Key Players in Down Markets
9.2.3 Downstream Market Trend Analysis
9.2.4 Sales Channel, Distributors, Traders and Dealers
10 Research Findings and Conclusion
Tables & Figures:
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
Research Methodology:
Alpha- Antitrypsin Deficiency Treatment Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|